Data as of Q4 2025 (Dec 31, 2025)

Caligan Partners LP

โ€ขCIK: 1727492โ€ขFiling: Q4 2025

**Caligan Partners LP** manages $1.1B across a concentrated portfolio of 21 positions. The fund exhibits significant conviction in select names, with its top holding, LQDA, representing $280.0M. Further notable allocations include ABVX at $195.8M and RVMD at $102.3M, suggesting a deep, thematic focus within its investment universe. This structure indicates a high-conviction, bottom-up approach to capital deployment.

Total AUM
$1.1B
+ $27.1M in options
QoQ Performance
+58.1%
Positions
19
+ 2 options
Top 10 Concentration
88.0%
Latest Filing
Q4 2025

Top Holdings Allocation

LQDA
ABVX
RVMD
MLYS
PCVX
EX9
ADMA
LQDA25.6%
ABVX17.9%
RVMD9.3%
MLYS9.2%
PCVX7.2%
EX96.2%
ADMA5.0%
TNGX3.0%

๐Ÿ“ˆ Biggest Buys

PCVX
VAXCYTE INC
NEW
7.2% of portfolio
TNGX
TANGO THERAPEUTICS INC
NEW
3.0% of portfolio
MAZE
MAZE THERAPEUTICS INC
NEW
2.1% of portfolio
RAPT
RAPT THERAPEUTICS INC
NEW
2.0% of portfolio
RVMD
REVOLUTION MEDICINES INC
+20.6%
9.3% of portfolio

๐Ÿ“‰ Biggest Sells

AGIOCALL
AGIOS PHARMACEUTICALS INC
-90.8%
0.2% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

EOLS
EVOLUS INC
SOLD
$25.4M
2GH
MERUS N V
SOLD
$20.4M
SLS
SELLAS LIFE SCIENCES GROUP I
SOLD
$3.7M
AURA
AURA BIOSCIENCES INC
SOLD
$1.4M

Changes from Q3 2025

NEW8 new positions
โ†‘7 increased
โ†“1 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023